Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2100-2108

  Van Der Vliet, Hans J J ^a,b   Koon, Henry B ^a   Yue, Simon C ^a   Uzunparmak, Burak ^a   Seery, Virginia ^a   Gavin, Marc A ^c   Rudensky, Alexander Y ^c   Atkins, Michael B ^a   Balk, Steven P ^a   Exley, Mark A ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; CD30 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MELANOMA; NATURAL KILLER T CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH2 CELL;

ADULT; AGED; CARCINOMA, RENAL CELL; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MALE; MELANOMA; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY;

EID: 34247524959     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1662     Document Type: Article

References (34)

1. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes for normal human bone marrows. Science 1976;193:1007-8.
2. Rosenberg SA, Mule JJ, Speiss PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-88.
3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.
4. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
5. Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135:2865-75.
6. Kronenberg M, Rudensky A. Regulation of immunity by self-reactive T cells. Nature 2005;435:598-604.
7. van der Vliet HJ, Molling JW, von Blomberg BM, et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004;112:8-23.
8. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 2005;116:87-93.
9. Tahir SM, Cheng O, Shaulov A, et al. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J Immunol 2001;167:4046-50.
10. Tachibana T Onodera H, Tsuruyama T, et al. Increased intratumor Vα24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 2005;11:7322-7.
11. Molling JW, Langius JA, Langendijk JA, et al. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 2007 (in press).
12. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52.
13. + suppressor T cells. J Exp Med 2001;193:F41-6.
14. Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005;54:1153-61.
15. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
16. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
17. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999;59:3128-33.
18. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
20. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA 2006;103:6659-64.
21. + regulatory T cells suppress NKT cell functions. Cancer Res 2003;63:4516-20.
22. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000;165:6037-46.
23. Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002;195:625-36.
24. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human Vα24 natural killer T cells. J Exp Med 2002;195:637-41.
25. + T cells. Clin Immunol 2005;115:10-8.
26. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
27. + NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients. Clin Immunol 2005;114:183-9.
28. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-9.
29. + T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-10.
30. Sereti I, Imamichi H, Natarajan V, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005;115:1839-47.
31. Shah MH, Freud AG, Benson DM, et al. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006;12:3993-6.
32. + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006;108:1571-9.
33. + regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169-77.
34. + regulatory T cells in cancer patients. Blood 2006;107:2409-14.